Phaseline

Companies › Mezzion Pharma

Mezzion Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Other.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Udenafil
Phosphodiesterase 5A inhibitor
PDE5APhase 3Single Ventricle Heart Disease–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05918211UdenafilPhase 3Single Ventricle Heart DiseaseOtherOct 2025

Targets

PDE5A (1)

Companies with the same targets

Aspargo Labs

Companies built like this

Tetra Discovery Partners Acer Therapeutics Shanghai Haiyan Pharmaceutical Technology Kaken Pharmaceutical Spine BioPharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.